NCT06870760 Pre-malignant States to Hematologic Malignancies in Firefighters
| NCT ID | NCT06870760 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Clonal Hematopoiesis of Indeterminate Potential |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2026-06 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2026-06 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic malignancies, and potentially other pathophysiological consequences.
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of personal health information. 2. Age ≥ 40-49 years at the time of consent (self-reported) 3. Ability of the participant to understand and comply with study procedures for the entire length of the study 4. Currently employed by Charlotte Fire Department (CFD) with at least 5 years on-the -job experience (self-reported) Exclusion Criteria: Anyone with a current diagnosis of a hematologic malignancy will be excluded.
Contact & Investigator
Larry Druhan, PhD
PRINCIPAL INVESTIGATOR
Wake Forest University Health Sciences
Frequently Asked Questions
Who can join the NCT06870760 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 49 Years, studying Clonal Hematopoiesis of Indeterminate Potential. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06870760 currently recruiting?
Yes, NCT06870760 is actively recruiting participants. Contact the research team at Megan.Lattanze@advocatehealth.org for enrollment information.
Where is the NCT06870760 trial being conducted?
This trial is being conducted at Charlotte, United States.
Who is sponsoring the NCT06870760 clinical trial?
NCT06870760 is sponsored by Wake Forest University Health Sciences. The principal investigator is Larry Druhan, PhD at Wake Forest University Health Sciences. The trial plans to enroll 300 participants.